Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 17/20 | 0.53 |
| ▸ | STIM1 | Q13586 | 3/20 | 0.43 |
| ▸ | ORAI1 | Q96D31 | 3/20 | 0.43 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17766382 | 0.89 | IL2 (0.58) | IL2STIM1ORAI1ORAI2MEN1 | |
| SCHEMBL16362409 | 0.88 | IL2 (0.46) | IL2STIM1ORAI1MEN1KMT2A | |
| SCHEMBL16362415 | 0.88 | IL2 (0.53) | IL2STIM1ORAI1ORAI2MEN1 | |
| SCHEMBL17766392 | 0.88 | IL2 (0.49) | IL2STIM1ORAI1TNF | |
| SCHEMBL17766377 | 0.84 | IL2 (0.52) | IL2STIM1ORAI1TNF | |
| SCHEMBL17766395 | 0.82 | IL2 (0.55) | IL2STIM1ORAI1ORAI2MEN1 | |
| SCHEMBL16362094 | 0.80 | IL2 (0.60) | IL2STIM1ORAI1ORAI2MEN1 | |
| SCHEMBL17766343 | 0.79 | IL2 (0.59) | IL2STIM1ORAI1ORAI2MEN1 | |
| SCHEMBL16361888 | 0.79 | IL2 (0.57) | IL2STIM1ORAI1ORAI2MEN1 | |
| SCHEMBL17766378 | 0.79 | IL2 (0.51) | IL2STIM1ORAI1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | claimed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | claimed |
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | disclosed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | disclosed |
| WO-2014203217-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2014-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | RYR2, NR2C2, CACNA1E | IL2 2831/4885STIM1 303/4885ORAI1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.